| 1 |
Cherian G, Thomas DW, Rule SA. The efficacy of low dose thalidomide in refractory/relapsed myeloma: a retrospective audit. Leuk Lymphoma 2006;47:2409-2411.
DOI
ScienceOn
|
| 2 |
Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968- 3977.
DOI
ScienceOn
|
| 3 |
Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-3114.
DOI
ScienceOn
|
| 4 |
Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218.
DOI
ScienceOn
|
| 5 |
Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
DOI
ScienceOn
|
| 6 |
Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-1412.
DOI
ScienceOn
|
| 7 |
Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160-3166.
DOI
ScienceOn
|
| 8 |
Sze DM, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr Cancer Drug Targets 2006;6:325-331.
DOI
ScienceOn
|
| 9 |
Patrick HE, Bowcock SJ. Ultra low dose thalidomide in myeloma revisited. Br J Haematol 2010;150:232-234.
|
| 10 |
Chang HJ, Lee JH, Do YR, et al. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant- candidate patients with newly diagnosed multiple myeloma. Korean J Intern Med 2011;26:403-409.
DOI
ScienceOn
|
webmaster
